jeudi 25 juillet 2019

Onco Actu du 25 juillet 2019


1. BIOLOGIE



Medulloblastoma Molecular Subtypes Refined With Single-Cell Transcriptome Data [Genome Web]











2.7 ETIOLOGIE - OBÉSITÉ



Measure waist size, not BMI to gauge risk of early death, new study shows [The Telegraph]











3.8 PRÉVENTION - ALIMENTATION



'Eating fish regularly' linked to lower risk of bowel cancer [NHS Choices]










4.12 BIOPSIES LIQUIDES



Freenome Snags $160M to Boost Blood Test for Early Cancer Detection [Xconomy]










Freenome Closes $160 Million Series B Financing to Advance Its Multiomics Blood Testing Platform for Early Cancer Detection [Business Wire]











Laser-focused on colorectal cancer test, Freenome wins $160M from marquee VC pack led by RA, Polaris [EndPoints]











4.9 DÉP., DIAG. & PRONO. - SEIN



Pilot Study of Five-Hour Molecular Test Accurately Distinguishes Malignant and Benign Breast Tumors [Johns Hopkins]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Researchers find evidence a cancer drug may be extended to many more patients [UT Southwestern]











Outcompeting cancer using a novel cell-competition mechanism [ecancer News]











5.10 TRAITEMENTS - ESSAIS



Targeted therapy erdafitinib effective for patients with advanced bladder cancer and specific gene mutations [MD Anderson Cancer Center]











5.12 IMMUNOTHÉRAPIES



Unfavourable Benefit-Risk Profile of Pembrolizumab Plus Pomalidomide and Dexamethasone in Multiple Myeloma [ESMO]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Immune therapy takes a "BiTE" out of brain cancer [Mass. General Hospital]











5.12.4 IMMUNOTHÉRAPIES - ESSAIS



Bristol-Myers hits snag in plan to catch Merck in lung cancer [Biopharma Dive]










Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck [Xconomy]











Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint of Overall Survival [BMS]











Bristol-Myers Squibb Provides Update on Part 2 of CheckMate -227 [BMS]











Bristol-Myers does it again, disappointing investors with another failed Opdivo PhIII as chemo combo flops [EndPoints]











Bristol-Myers releases mixed Opdivo lung cancer results [Reuters]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



TScan Lands $48M for Better, Safer T-Cell Receptor Cancer Therapies [Xconomy]











Novartis backs Harvard spinout's quest to build TCR repository in $48M round [EndPoints]











5.16 TRAITEMENTS - CHIRURGIE



Cellular soldiers designed to kill cancer cells that get loose during surgery, stop metastasis [Vanderbilt University]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Sharpless outlines FDA’s key priorities for advancing public health [EndPoints]











6.1 OBSERVATION



Residents of US Cancer Town diagnosed at 'highly unusual' rates, study says [The Guardian]











Relaxed UK salt policy tied to more heart disease, cancers [Reuters]











6.2 IMPLANTS MAMMAIRES



Allergan Recalls Textured Breast Implants Linked To Rare Type Of Cancer [NPR]











Allergan recalls textured breast implant tied to rare cancer [STAT]











Breast Implants Linked to Rare Cancer Are Recalled Worldwide [NY Times]











Allergan recalls textured breast implants worldwide [Reuters]











Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders [Allergan]











The FDA Takes Action to Protect Patients from Risk of Certain Textured Breast Implants; Requests Allergan Voluntarily Recall Certain Breast Implants and Tissue Expanders from the Market: FDA Safety Communication [FDA]